NYSEARCA:XBI - SPDR S&P Biotech ETF Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $78.03 +2.07 (+2.73 %) (As of 03/30/2020 04:00 PM ET) Add Today's Range$75.22Now: $78.03▼$78.1150-Day Range$65.95MA: $86.67▼$98.3552-Week Range$62.94Now: $78.03▼$98.79Volume4.05 million shsAverage Volume7.27 million shsMarket Capitalization$3.55 billionP/E RatioN/ADividend Yield0.01%BetaN/A ProfileAdvanced ChartDividendInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More Basic Details Issuer SSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webhttp://www.spdrs.com/ Phone+1-866-7872257 Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Fund Statistics Assets Under Management$3.51 billion Average Daily Volume$11.13 million Discount/Premium0.05% ETF Expenses Management Fee0.35% Other Expenses0.00% Total Expenses0.35% Fee Waiver0.00% Net Expenses0.35%Administrator, Advisor and Custodian AdministratorSSGA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company Trustee Lead Market MakerVirtu Financial Receive XBI News and Ratings via Email Sign-up to receive the latest news and ratings for XBI and its competitors with MarketBeat's FREE daily newsletter. AMEX:XBI Rates by TradingView SPDR S&P Biotech ETF (NYSEARCA:XBI) Frequently Asked Questions How has SPDR S&P Biotech ETF's stock been impacted by COVID-19 (Coronavirus)? SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XBI shares have decreased by 1.2% and is now trading at $78.03. View which stocks have been mosted impacted by Coronavirus. How often does SPDR S&P Biotech ETF pay dividends? What is the dividend yield for SPDR S&P Biotech ETF? SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Shareholders of record on Monday, December 23rd will be given a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 annualized dividend and a yield of 0.00%. The ex-dividend date is Friday, December 20th. View SPDR S&P Biotech ETF's dividend history. Has SPDR S&P Biotech ETF been receiving favorable news coverage? Media stories about XBI stock have trended very negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSPDR S&P Biotech ETF. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include iShares Nasdaq Biotechnology ETF (IBB), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Alibaba Group (BABA), Advanced Micro Devices (AMD), AT&T (T), Cisco Systems (CSCO), Micron Technology (MU) and Walt Disney (DIS). Who are SPDR S&P Biotech ETF's key executives? SPDR S&P Biotech ETF's management team includes the following people: James E. Ross, President, Trustee (Age 52)Peter A. Ambrosini, Chief Compliance Officer (Age 69)Michael P. Riley, Vice President (Age 44)Gary L. French, Treasurer (Age 64)John W. Clark, Assistant Treasurer (Age 46)Matthew W. Flaherty, Assistant Treasurer (Age 42)Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)Mary Moran Zeven, Secretary (Age 52)Scott M. Zoltowski, Assistant Secretary (Age 44)Dave Kelly, Independent Trustee What is SPDR S&P Biotech ETF's stock symbol? SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI." Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of America Corp DE (10.48%), Cumberland Advisors Inc. (0.50%), Whittier Trust Co. (0.47%), Thrivent Financial for Lutherans (0.45%), Main Management ETF Advisors LLC (0.44%) and Eaton Vance Management (0.40%). Which institutional investors are selling SPDR S&P Biotech ETF stock? XBI stock was sold by a variety of institutional investors in the last quarter, including IMC Chicago LLC, Reilly Financial Advisors LLC, Baird Financial Group Inc., Nomura Asset Management Co. Ltd., Northwestern Mutual Wealth Management Co., Biltmore Family Office LLC, OLD Second National Bank of Aurora, and Deltec Asset Management LLC. Which institutional investors are buying SPDR S&P Biotech ETF stock? XBI stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Tygh Capital Management Inc., Orion Portfolio Solutions LLC, Segment Wealth Management LLC, Q3 Asset Management, Howard Capital Management, Capital Advisors Inc. OK, and Tower Research Capital LLC TRC. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SPDR S&P Biotech ETF's stock price today? One share of XBI stock can currently be purchased for approximately $78.03. How big of a company is SPDR S&P Biotech ETF? SPDR S&P Biotech ETF has a market capitalization of $3.55 billion. View additional information about SPDR S&P Biotech ETF. What is SPDR S&P Biotech ETF's official website? The official website for SPDR S&P Biotech ETF is http://www.spdrs.com/. How can I contact SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257. MarketBeat Community Rating for SPDR S&P Biotech ETF (NYSEARCA XBI)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 113 (Vote Outperform)Underperform Votes: 132 (Vote Underperform)Total Votes: 245MarketBeat's community ratings are surveys of what our community members think about SPDR S&P Biotech ETF and other stocks. Vote "Outperform" if you believe XBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/30/2020 by MarketBeat.com StaffFeatured Article: How is a management fee different from a performance fee?
